Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Unknown 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 3Plasma cell 2Breast 2Sarcoma 1Myeloid 1Head & Neck 1Genitourinary 1CNS 1

Conditions

Multiple Myeloma 725Neoplasms, Plasma Cell 135Lymphoma, Non-Hodgkin 118Lymphoma 111Recurrence 103Leukemia, Lymphocytic, Chronic, B-Cell 99Precursor Cell Lymphoblastic Leukemia-Lymphoma 93Leukemia, Myeloid, Acute 92Hodgkin Disease 92Lymphoma, Large B-Cell, Diffuse 83Leukemia 75Lymphoma, Mantle-Cell 71Myelodysplastic Syndromes 70Lymphoma, Follicular 69Burkitt Lymphoma 60Lymphoma, B-Cell, Marginal Zone 59Neoplasms 54Lymphoma, Large-Cell, Immunoblastic 54Waldenstrom Macroglobulinemia 42Myeloproliferative Disorders 39Leukemia, Myelomonocytic, Chronic 39Leukemia, Myeloid, Chronic-Phase 39Primary Myelofibrosis 38Immunoglobulin Light-chain Amyloidosis 38Hematologic Neoplasms 38Lymphoma, T-Cell, Cutaneous 36Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 35Lymphoma, Large-Cell, Anaplastic 34Leukemia, Myeloid, Accelerated Phase 34Blast Crisis 33

Interventions

siltuximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Castleman Disease × Plasma cell × Clear all
NCT00412321 2014-07-01

A Safety and Efficacy Study of CNTO 328 in Patients With B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease

Centocor, Inc.

Phase 1 Completed
67 enrolled
LymphoidPlasma cell

Castleman Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma

NCT00891280 2011-06-15

Dose-escalation Study of Oral CX-4945

Cylene Pharmaceuticals

Phase 1 Unknown
55 enrolled
BreastLymphoidPlasma cell

Breast Neoplasms, Castleman Disease, Multiple Myeloma, Inflammatory Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡